Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645132 | 0.86 | PSIP1 (0.48) | PSIP1NR1H2NR1H3ALDH1A1POLB | |
| SCHEMBL12900979 | 0.83 | DDB1 (0.43) | NR1H2NR1H3ALDH1A1GAA | |
| SCHEMBL6208314 | 0.79 | HSD11B1 (0.53) | PSIP1POLBHSD11B1MEP1BMTNR1B | |
| SCHEMBL18325885 | 0.79 | GAA (0.47) | PSIP1ALDH1A1POLBGAA | |
| SCHEMBL14773591 | 0.77 | TP53 (0.52) | PSIP1NR1H2NR1H3ALDH1A1GAA | |
| SCHEMBL27830685 | 0.77 | PSIP1 (0.46) | PSIP1NR1H2NR1H3ALDH1A1POLB | |
| SCHEMBL10741172 | 0.76 | PSIP1 (0.48) | PSIP1NR1H2NR1H3ALDH1A1POLB | |
| SCHEMBL18184671 | 0.76 | PSIP1 (0.59) | PSIP1NR1H2NR1H3 | |
| SCHEMBL17263850 | 0.75 | PSIP1 (0.68) | PSIP1NR1H2NR1H3ALDH1A1HSD11B1 | |
| SCHEMBL16964583 | 0.75 | PSIP1 (0.52) | PSIP1NR1H2NR1H3ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252761-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-8278450-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-02 | — | — | US | disclosed |
| US-20120095233-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110184178-A1 | POLYMORPHS OF 5-(3-(ETHYLSULFONYL)PHENYL)-3,8-DIMETHYL-N-(1-METHYLPIPERIDIN-4-YL)-9H-PYRIDO[2,3-B]INDOLE-7-CARBOXAMIDE AND METHODS OF USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095233-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | PSIP1 3076/4885NR1H2 3919/4885NR1H3 3722/4885 |
| US-20110184178-A1 | POLYMORPHS OF 5-(3-(ETHYLSULFONYL)PHENYL)-3,8-DIMETHYL-N-(1-METHYLPIPERIDIN-4-YL)-9H-PYRIDO[2,3-B]INDOLE-7-CARBOXAMIDE AND METHODS OF USE THEREFOR | TPH1, CYP3A7, HLA-DRB1 | PSIP1 1064/4885NR1H2 2066/4885NR1H3 1489/4885 |
| US-20120252761-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | PSIP1 3076/4885NR1H2 3919/4885NR1H3 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.